BALVERSA® unlocks a new direction in 2L+ therapy for LA/mUC patients1

BALVERSA® is a monotherapy indicated for the treatment of adult patients with unresectable LA/mUC harbouring susceptible FGFR3  alterations and who have progressed during or following at least one line of therapy containing a PD-1 or PD-(L)1 inhibitor in this disease setting.1
BALVERSA® no se encuentra comercializado en España.

Scan the QR code to see the full BALVERSA® SmPC.

▼ BALVERSA® is subject to additional monitoring. This will allow for quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms can be found at https://www.janssenmediacalcloud.com/en-us/report-an-adverse-event.

2L: second-line; FGFR3: fibroblast growth factor receptor 3; LA: locally advanced; mUC: metastatic urothelial carcinoma; PD-1: programmed cell death protein 1; PD-(L)1: programmed cell death ligand 1;
SmPC: summary of product characteristics.